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Abstract
Epigenetic processes–including DNA methylation–are increasingly seen as having a fundamental role in chronic diseases
like cancer. DNA methylation patterns offer a route to develop prognostic measures based directly on DNA measurements,
rather than less-stable RNA measurements. A novel DNA methylation-based measure of the co-ordinated interactive
behaviour of genes is developed, in a network context. It is shown that this measure reflects well the co-regulatory
behaviour linked to gene expression (at the mRNA level) over the same network interactions. This measure, defined for pairs
of genes in a single patient/sample, associates with overall survival outcome independent of known prognostic clinical
features, in several independent data sets relating to different cancer types. In total, more than half a billion CpGs in over
1600 samples, taken from nine different cancer entities, are analysed. It is found that groups of gene-pair interactions which
associate significantly with survival identify statistically significant subnetwork modules. Many of these subnetwork modules
are shown to be biologically relevant by strong correlation with pre-defined gene sets, such as immune function, wound
healing, mitochondrial function and MAP-kinase signalling. In particular, the wound healing module corresponds to an
increase in co-ordinated interactive behaviour between genes for worse prognosis, and the immune module corresponds to
a decrease in co-ordinated interactive behaviour between genes for worse prognosis. This measure has great potential for
defining DNA-based cancer biomarkers. Such biomarkers could naturally be developed further, by drawing on the rapidly
expanding knowledge base of network science.
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Introduction
Epigenetic information is stored in the genome in the form of
heritable modifications to the chemical structure of DNA, such as
methylation of CpG di-nucleotides. Epigenetic information can be
modulated during the lifetime of an organism by environmental
cues [1–3] and these changes persist in subsequent mitoses, leading
to an acquired change of phenotype. As such, epigenetics can be
considered to be an interface between the genome and the
environment, and consequently also a conduit for environmental
risk factors.
Alterations in DNA methylation (DNAm) levels are among the
earliest changes in human carcinogenesis [1], and hence offer
novel strategies to identify individuals who might be at risk of
developing such illnesses or individuals with early stage cancers.
However, to proceed with developing such tests, measures relating
to DNA methylation are needed, which can be consistently linked
to clinically relevant differences, such as patient outcome. Per-gene
measures of DNA methylation have been shown to be relevant to
the study of cancer genomics [4], and network models and
measures naturally reflect the collective behaviour of groups of
similar items, such as genes, and their interactions with one
another. As such, they may help with the development of DNAm-
based biomarkers which take account of such collective and
interactive behaviour of genes.
As a cancer progresses, its signalling and control networks are
re-arranged (‘re-wired’), and this drives adaptive alterations in
phenotype, which are advantageous for the cancer [5]. Previous
research by other authors [6] found that patient survival outcome
in breast cancer (BRCA) could be predicted well by network
models of this re-wiring, based on gene expression data. DNAm
patterns are more stable than gene expression patterns, because
DNAm measurements are taken directly from DNA, whereas gene
expression measurements must come via RNA. Hence, DNAm
patterns might be expected to lead to more reliable disease
biomarkers than gene expression patterns would be able to. Here,
we develop a measure of network interaction ‘co-ordinatedness’,
between pairs of genes, based on DNA methylation data. We show
that this measure, calculated for pairs of genes, is highly associated
with co-regulatory behaviour linked to gene expression (at the
mRNA level) over the same network interactions/pairs of genes.
We show that this measure associates significantly with overall
survival outcome independent of known prognostic markers in
several data sets and cancer types, and that groups of these
significant gene-gene network interactions identify subnetwork
modules, with a well-controlled false discovery rate. Of these
significant subnetwork modules, one module corresponds very
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strongly to wound healing, with its gene-gene interactions
displaying an increase in co-ordinated behaviour with worse
disease prognosis. Another of these significant subnetwork modules
corresponds very strongly to immune function, with its gene-gene
interactions predominantly showing a decrease in co-ordinated
behaviour with worse disease prognosis. Our findings provide the
basis for further development of independent DNA methylation
oncomarkers in the context of network science.
Results
The DNA Methylation Network Correlation Measure
The DNA methylation (DNAm) network correlation measure
quantifies the extent to which the DNA methylation profiles of a
pair of genes ‘explain’ each other. It is based only on
measurements of the DNA methylation profiles of this pair of
genes, and it acts as a surrogate for a measure of the extent to
which this pair of genes behave interactively. Such interactive
behaviour may include transcriptional regulation or other types of
biochemical interaction, and a pair of genes will affect each other’s
transcriptional behaviour or other biochemical functioning most
directly as a result of their own expression levels. An increase in
methylation level around the gene promoter is certainly correlated
with a decrease in the expression level of the gene, although which
of these occurs first is not clear [7]. An increase in methylation
level in the gene body is related less certainly to effects on gene
transcriptional and translational behaviour, which may include
increased expression level and alternatively spliced gene products
[7]. Hence, there may be a number of components of the variation
of the methylation profile of a gene which are significant in terms
of their correlation with different transcriptional effects of that
gene. The methylation profile of a gene is taken as a surrogate for
these various interactive effects in the DNAm network cross
correlation measure, which quantifies the extent to which these
interactive effects or patterns in a pair of genes explain each other,
as reflected in the DNA methylation profiles.
The DNAm network cross correlation measure is defined by
analogy to Canonical Correlation Analysis (CCA) [8] (see
‘methods and models’ for formal definitions). CCA aims to
discover linear combinations of variables of one type, and linear
combinations of variables of another type, so that these
combinations best ‘explain’ each other. In this context, a particular
way of combining (by scaling and adding) the deviations from the
mean methylation profile at a number of locations within one gene
might be particularly effective at explaining a particular combi-
nation (again, by scaling and adding) of the deviations from the
mean methylation profile at a number of locations in another
gene, and vice-versa. There will probably be fewer ways in which
the methylation levels of these genes vary across the samples, than
there are locations at which methylation is measured, along each
gene; this is because the methylation level at many locations along
a gene is highly correlated. CCA finds the most important
components of this variation across samples (in terms of these
linear combinations of variables of each type, i.e., methylation
measurements in each gene) which both these types of variables
(i.e., DNA methylation in the two genes considered) have in
common.
CCA finds linear combinations of the two types of variables that
covary. Because linear combinations are evaluated, the two types
of variables can be of a different number. The DNAm network
cross correlation measure therefore evaluates the extent to which,
in an individual sample, these combinations in this pair of types of
variables explain each other. The covariation is assessed against
typical variability in such variables. Such variation is assessed in
terms of the evaluated statistics. Variation is understood in terms
of the population covariance matrix, inherent to healthy samples,
the methylation profile for one gene makes up the variables of one
type, and the variables of that type are the methylation points, i.e.,
CpGs, along that gene. There are many sources of variation.
When the DNAm network cross correlation measure is large (i.e.,
close to 1), the corresponding pair of genes explain each others
transcriptional or translational behaviour (as reflected in their
methylation profiles) well, or have otherwise well-correlated
interactive behaviour, for the corresponding sample (patient); see
figure 1.
Application of the DNA Methylation Network Correlation
Measure to Data
The DNAm network correlation measure was developed and
evaluated in the context of DNAm data obtained via the Illumina
Infinium Human Methylation 450 K platform, from samples from
cancer patients made publicly available via The Cancer Genome
Atlas (TCGA) project [9–11], relating to nine different cancer
types. Details of the number of samples (patients) for which DNA
methylation and survival analysis were carried out, for each data
set, appear in table 1.
For each data set, considering all possible pairs of the 14800
genes available would require more than 108 comparisons, each
based on the data for a pair of genes across all the samples in that
data set. Further, it is possible that spurious correlations could arise
if all possible pairs of genes were considered in this way. For
example, the expression and regulatory patterns of a pair of genes
may be highly correlated if they are both part of the same
signalling pathway, even if they do not directly interact. To avoid
problems due to the high number of tests inherent to considering
all pairwise gene interactions, we restricted the number of pairs of
genes for which the DNAm network correlation measure was
considered. The DNAm network correlation measure was only
calculated for a pair of genes, and subsequent analyses were only
carried out, if that pair of genes was listed as taking part in a
known biochemical interaction. We note that [6] proposed such a
restriction for pairwise gene interactions, and applied it success-
fully. A list of such interactions was downloaded from http://
www.pathwaycommons.org, and was used as a canonical human
interactome map.
Comparing the DNA Methylation Network Correlation
Measure with Gene Expression Network Correlation
In order to test whether a major component of the interactive/
co-regulatory behaviour quantified by the DNA methylation
network correlation measure corresponds to that which can be
measured by mRNA levels, the following procedure was carried
out. For the five data sets included in the subsequent DNA
methylation analysis for which sufficient gene expression data (in
the form of mRNA levels) were available, for each pair of genes for
which the DNAm network correlation measure was calculated, the
Spearman correlation coefficient of the mRNA expression levels
for that pair of genes was calculated, across all the cancer samples
with gene expression data available for that tumour type. For each
of these pairs of genes, the mean of the DNA methylation network
correlation measure was also calculated across all available
(cancer) samples. The significance of association of the mean
DNAm network correlation measure with the mRNA expression
(gene expression) network correlation coefficient across all pairs of
genes is shown in table 2, for each data set. Note that table 2 shows
different numbers of samples for each cancer type to table 1,
because the DNA methylation and gene expression analyses were
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based mostly on different samples from the same cancer type.
Absolute values of these correlation measures are compared,
because negative values mean different things in relation to the
DNAm network correlation measure, and to the correlation
coefficient of the gene expression data. For each data set, a
Spearman correlation test comparing these network correlation
measures across all pairs of genes is very significant, with
pƒ2:3|10{17 for all five data sets considered. Hence, it is
concluded that a major component of the interactive behaviour
quantified by the DNAm network correlation measure is the
interactive (co-regulatory) behaviour corresponding to gene
expression, at the mRNA level.
In many (approximately one third) of gene-pair comparisons
made by the DNAm network correlation measure, it was
calculated that there are two or more significant components of
covariation between these pairs of genes, as determined by
examining the corresponding cross-covariance matrices. Each
such calculation was carried out by performing a singular value
decomposition to estimate the variances corresponding to the
main components of variation, and comparing these to empirical
null model variances calculated similarly after randomising the
original data, as in previous genomics studies by other authors
[12]. The most likely candidates for these additional components
of covariation which are measured by the DNAm network
Figure 1. The DNAmethylation network interaction measure. A combination of the variation of the healthy methylation profiles in regions (a)
and (b) of gene X explains well/is well-explained by a combination of the variation of the healthy methylation profiles in regions (c) and (d) of gene Y.
The green cancer sample varies by a large amount about the mean methylation profile and in a typical way in these regions in both genes. Hence, the
green sample corresponds to a high level of network interaction co-ordinatedness, as measured by the DNA methylation network interaction
measure, rXY~1. The variation in the other regions of these genes do not well-explain each other, and so the red sample, which varies by a large
amount in these other regions and varies less and in an atypical way in regions (a)–(d), corresponds to a low level of network interaction co-
ordinatedness, rXY~0:07. Genes X and Y are likely to have different numbers of methylation measurement locations (i.e., variables X and Y are of
different dimension). The ordering of the measurement locations has no influence on the calculation of r, as long as the ordering is consistent across
samples.
doi:10.1371/journal.pone.0084573.g001
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correlation measure, beyond gene expression, include other
components of biochemical interactive behaviour such as those
associated with alternatively spliced forms of the gene product
(such alternatively spliced forms are thought to be linked to DNA
methylation, [7]). However, it is not possible to test these
hypotheses further using the publicly available data analysed here.
A further study, involving collection of additional data such as
RNA-seq or other transcriptome-level data collected with DNA
methylation data, would have the potential for investigating such
additional possibilities.
Association of the DNAm Network Correlation Measure
with Patient Survival Outcome
The DNA methylation network correlation measure was tested
against patient survival outcome, and further methodology was
developed in this context, in order to develop the DNAm network
correlation measure as a basis for prognostic biomarkers. For each
data set, for each pair of genes, the association of the DNAm
network correlation measure with patient overall survival outcome
was tested by Cox regression, adjusted for clinical covariates. This
adjustment for clinical covariates was carried out in order to
develop a novel prognostic measure which is independent of
known prognostic clinical features, such as age, disease stage and
grade, and to take account of possible confounding (see ‘methods
and models’ for further details). Heatmaps showing p-values of
association of the DNAm network correlation measure with
patient survival outcome, for the BRCA data set, for all
interactions and for just those which appear in the canonical
human interactome map, appear in figure S1, together with
equivalent heatmaps produced from randomly generated p-values,
to show the structure in this network model provided by the
canonical human interactome map.
The canonical human interactome map defines 276136
interactions for the 8614 genes which are also present in each of
the data sets considered here. For each of the 9 data sets, the
276136 p-values resulting from the tests of association with patient
overall survival outcome (adjusted for clinical covariates) for each
of these interactions are plotted in histograms, which appear in
figure 2. For the COAD and LIHC data sets there is no
association with survival. However for the other seven data sets
(cancer types), and in particular BRCA, KIRC, LUAD, LUSC
and UCEC, the concentration of p-values close to p~0 shows that
there are many pairs of genes for which the DNAm network
correlation measure associates significantly with survival. It is
important to note that the poor correlation for certain data sets is
strongly linked, as would be expected, to the size of the data sets,
and in particular to the number of events in the data sets (table 1).
Applying these methods to larger data sets will be necessary for the
development and validation of robust biomarkers.
Identification of Significant and Biologically Relevant
Subnetworks
The data sets for which the DNAm network correlation
measure did not show a correlation with survival outcome,
COAD and LIHC, were excluded from the subsequent analyses,
which proceeded with the seven remaining data sets, BLCA,
BRCA, HNSC, KIRC, LUAD, LUSC and UCEC. If genes
represent network nodes, significant subnetworks, modules, or
motifs can be derived from the canonical human interactome map,
by retaining the network edges (i.e., pairwise interactions between
genes) which correspond to the DNAm network correlation
measures which associate significantly with patient overall survival
outcome. A significant subnetwork, module, or motif is then made
up of genes which are connected by edges which are significantly
associated with survival outcome. Some genes are connected to a
large number of other genes in the canonical interactome map
(i.e., they have high degree). If edges are defined as significant
when they correspond to pv0:05 of association with patient
survival outcome, then a node (gene) of high degree would be
expected to be connected to some other genes by significant edges
which are in fact false positives. If several nodes of high degree are
connected together by false positives in this way, it would result in
a subnetwork being falsely declared significant; this could happen
anywhere in the canonical interactome map where several high-
degree nodes are connected together. To mitigate this effect, for
each node (gene), the p-values of association with survival outcome
for each of its connected edges (interactions) were converted to
FDR (false discovery rate) adjusted q-values [13] with respect to
that node (gene). Each edge (interaction) was then only marked as
significant if it associated significantly with patient survival
Table 1. Number of samples in each data set.
Samples Events
BLCA 108 31
BRCA 173 23
COAD 237 36
HNSC 266 89
KIRC 265 91
LIHC 50 20
LUAD 143 45
LUSC 141 48
UCEC 276 28
Number of samples (patients) in each data set, together with number of events
(i.e., number of patients who died before the end of the respective study).
Abbreviations as follows: Bladder Urothelial Carcinoma (BLCA), Breast Invasive
Carcinoma (BRCA), Colon Adenocarcinoma (COAD), Head and Neck Squamous
Cell Carcinoma (HNSC), Kidney Renal Clear Cell Carcinoma (KIRC), Kidney Renal
Papillary Cell Carcinoma (KIRP), Liver (LIHC), Lung Adenocarcinoma (LUAD),
Lung Squamous Cell Carcinoma (LUSC), and Uterine Corpus Endometrioid
Carcinoma (UCEC).
doi:10.1371/journal.pone.0084573.t001
Table 2. Significance of association of the DNAm network
correlation measure with gene expression network
correlation.
Data set Samples p-value
BRCA 590 4.4610219
COAD 174 5610221
KIRK 72 3.2610217
LUSC 155 6610238
UCEC 54 2.3610217
For each gene-pair for which the DNAm network correlation measure is
calculated, for which there are also mRNA expression (gene expression) data
available, the Spearman correlation coefficient comparing the expression levels
of that pair of genes is calculated across the available samples in a given data
set (tumour samples only). For each pair of genes, the mean of the DNAm
network correlation measure across the available samples in that data set is also
calculated. These mean DNAm network correlation and expression network
correlation measures are compared across all pairs of genes for each data set,
with the corresponding p-values (Spearman correlation test) shown in the table.
doi:10.1371/journal.pone.0084573.t002
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Figure 2. p-value histograms, showing the association of the DNA methylation network correlation measure with patient overall
survival outcome, for all data sets. For each network edge, which connects a pair of genes (nodes), Cox regression is used to calculate a p-value
A DNA Methylation Network Interaction Measure
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outcome with qv0:05 according to both the nodes (genes)
connected by that edge.
Significant subnetworks, modules, and motifs found in this way
were tested for biological relevance, by checking the genes
comprising each subnetwork using gene set enrichment analysis
(GSEA) [14]. For each significant subnetwork, module or motif,
6811 gene set definitions, downloaded from the Broad Institute
Molecular Signatures Database (http://www.broadinstitute.org),
were tested one by one for enrichment by the genes which
comprise the respective subnetwork, module, or motif; further
details about these gene sets can be found at that website. These
enrichment tests were carried out using a one-sided Fisher’s exact
test, and if any of the 6811 gene sets showed significant enrichment
(qv0:05) by the genes comprising a subnetwork, module, or motif,
it was marked as having biological relevance, according to the
findings of previous work. The numbers of significant subnetworks,
modules and motifs, arranged according to number of genes/
nodes, and the numbers of these found to be biologically relevant,
appear in table 3.
To check how well this methodology guards against falsely
declaring subnetworks as significant, exactly the same process of
significant subnetwork identification was applied to p-values
randomly generated by sampling from a uniform(0,1) distribution
and assigned to the 276136 interactions, and this process was
repeated 104 times. Table 4 shows the number of null subnetworks
produced, of each size, in total over the 104 iterations. If there
were no association of the DNAm network correlation measure
with survival outcome (which would correspond to uniformly
distributed p-values across these features), the expected number of
3-node subnetworks falsely declared as significant in a particular
data set would be 4.0, the expected number of falsely identified 4-
node subnetworks would be 0.34, and for 5 nodes the expected
number would be 0.037. Comparison of these numbers with
table 3 and the definition of the false discovery rate implies (taking
into account these seven data sets) FDRƒ1 for 3 node
subnetworks, FDRƒ0:34 for 4 node subnetworks, and
FDRƒ0:037 for 5 node subnetworks. Further, no individual gene
appeared in these null subnetworks with at least 5 nodes more than
twice out of the 104 iterations. As these small motifs of 3 and 4
nodes are of less interest in general, and because by excluding
them the subnetwork false discovery rate is well-controlled, in the
subsequent analysis, only subnetworks, modules and motifs with at
least 5 nodes were considered as significant.
A network edge which is significant due to a correlation between
a higher value of the DNAm network correlation measure and
worse patient survival time (i.e., hazard ratio, HRw1), corre-
sponds to an increasing tendency of the genes (nodes) at either end
of this network edge to explain each other’s regulatory behaviour,
the worse the prognosis of the cancer. This can be thought of as an
increase in network interaction ‘co-ordinatedness’ between these
genes corresponding to worse disease prognosis, or a ‘positive
network re-wiring’ that is adaptively advantageous for the cancer.
The opposite effect, where a network edge is significant due to a
correlation between a lower value of the DNAm network
correlation measure and worse patient survival time (i.e., hazard
ratio, HRv1), is equivalent to a decrease in network interaction
co-ordinatedness for worse disease prognosis, or ‘negative network
re-wiring’. The proportion of significant network edges with
HRw1 (increase in network interaction co-ordinatedness for
worse disease prognosis) is shown for each data set in table 5.
Smaller Significant and Biologically Relevant Network
Modules of Interest
Detailed consideration of the smaller network modules identi-
fied as significant, and biologically relevant, confirms their
relevance to cancer biology. Amongst the gene sets significantly
enriched by the significant network modules, as well as numerous
specific cancer gene sets, gene sets appear multiple times relating
to JAK-STAT signalling, WNT signalling, GPCR signalling,
EGFR signalling, VEGF signalling, interleukin activity, neutrophil
activity/response to wounding, immune activity, metabolic
activity/TCA cycle/mitochondria, chromosome maintenance,
developmental processes/stem cells, programmed cell death,
response to UV/DNA damage repair/Fanconi anemia, cell cycle,
transcriptional regulation, transcriptional activity, and transport/
trafficking.
Six examples of smaller network modules identified as
significant and biologically relevant are shown in figure 3; these
include modules related to wound healing (associated with cancer
invasion and progression to new sites), immune function (associ-
ated with stifling the body’s ability to fight the cancer,
mitochondrial function (associated with increased energy produc-
(adjusted for clinical covariates), which represents the association of the DNAm network correlation measure for that edge with patient survival
outcome. For COAD and LIHC, there is no association of the DNAm network correlation measure with patient outcome. For the other data sets
(cancer types), and in particular BRCA, KIRC, LUAD, LUSC and UCEC, the collection of p-values close to 0 shows that, for those data sets, the DNAm
network correlation measure for many network edges is associated with patient outcome.
doi:10.1371/journal.pone.0084573.g002
Table 3. Number of significant subnetworks, modules and
motifs.
Nodes BLCA BRCA HNSC KIRC LUAD LUSC UCEC
3 4 (1) 19 (8) 9 (5) 19 (6) 38 (10) 11 (2) 8 (1)
4 1 (0) 9 (3) 2 (0) 9 (3) 12 (6) 5 (1) 5 (1)
5 2 (2) 1 (1) 1 (0) 1 (0) 5 (1) 0 (0) 4 (1)
6 1 (0) 1 (0) 1 (0) 1 (0) 2 (0) 1 (0) 2 (2)
7 0 (0) 1 (0) 1 (0) 1 (1) 2 (0) 0 (0) 0 (0)
8 0 (0) 0 (0) 0 (0) 1 (1) 2 (0) 0 (0) 1 (1)
9 1 (1) 1 (0) 0 (0) 2 (0) 1 (1) 1 (0) 0 (0)
10 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0) 0 (0)
11 0 (0) 0 (0) 1 (0) 0 (0) 1 (1) 0 (0) 2 (1)
13 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0)
14 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0) 0 (0)
16 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0) 0 (0)
17 1 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
18 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0)
24 1 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
27 0 (0) 0 (0) 1 (0) 0 (0) 0 (0) 0 (0) 0 (0)
373 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0)
770 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 0 (0)
The number of significant subnetworks, modules and motifs found with each
number of nodes (genes) is shown for each data set. Of these, the numbers
found to have biological relevance (as determined by gene set enrichment
analysis) are shown in brackets. Modules and larger subnetworks subsequently
plotted in figures 3 and 4 are shown in bold.
doi:10.1371/journal.pone.0084573.t003
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tion required for cancer proliferation) and MAP-kinase signalling
(associated with regulation of cell proliferation). Summaries of the
genes/nodes which appear in these network modules, and of the
respective significantly enriched gene sets, appear in tables 6 and 7
(wound healing), tables 8 and 9 (immune), table S1 (mitochondri-
al), table S2 (MAP-kinase), and tables S3 and S4 (largest
biologically significant subnetworks found in the BLCA and
BRCA datasets, respectively).
Importantly, the network interactions in the wound healing
module predominantly show an increase in network interaction
co-ordinatedness with worse disease prognosis, indicating a
tendency towards co-ordinated behaviour of these genes in
support of metastatic processes. Conversely, the network interac-
tions in the immune subnetwork module predominantly show a
decrease in network interaction co-ordinatedness with worsening
disease prognosis, suggesting a degradation of the body’s own
defences against the tumour. Hence, the DNA methylation
network correlation measure, as a surrogate measure of more
general interactive behaviour of genes, reflects increases and
decreases in interactive behaviour in subnetwork modules which
would be expected according to their biological function and role
in disease.
The genes which comprise the wound healing module, and an
outline of their biological roles, are as follows. ELANE is
neutrophil elastase; it is secreted by neutrophils and macrophages
during inflammation, and destroys bacteria and host tissue [15].
KNG1 is kininogen 1, which uses alternative splicing to generate
two different proteins, including HMWK which is important for
coagulation of blood [16]. SERPINE1 encodes the serpin
peptidase inhibitor, which plays a key role in the inhibition of
fibrinolysis (the physiological breakdown of blood clots) [17]. F2R
is proteinase-activated receptor 1, which is involved in the
regulation of thrombotic response (clotting in blood vessels) [18].
F5 is factor five, a protein of the coagulation system; its deficiency
leads to predisposition for haemorrhage [19]. CSF3 is granulocyte
colony-stimulating factor, which promotes the differentiation and
proliferation of blood cells [20]. ITGAM is integrin alpha M,
which mediates inflammation by regulating leukocyte adhesion
and migration [21]. THY1 is cluster of differentiation 90, which
amongst other functions has a role in cell adhesion and migration
[22].
The genes which comprise the immune module, and an outline
of their biological roles, are as follows. HLA-A is a human
leukocyte antigen (HLA); HLA constitute a large subset of the
major histocompatibility complex (MHC, which mediates the
interaction of immune system white blood cells) [23]. ITGAV is
the vitronectin receptor integrin (integrins mediate attachment
between a cell and its surroundings); vitronectin is found in serum
and the extracellular matrix (ECM) and has been implicated in
tumour malignancy [24]. SDC4 is syndecan 4, which interacts
with ECM, anticoagulants, and growth-factors, and regulates the
actin cytoskeleton, cell adhesion, and cell migration [25]. SDCBP
is syndecan binding protein, which is thought to function as an
adaptor protein, coupling the important developmental/pluripo-
tency transcription factor SOX4 to the interleukin-5 receptor
(which stimulates immune B-cell growth) [26]. CD247 encodes a
component of the zeta-chain, which is part of the immune T-cell
surface antigen receptor (TCR), which serves antigen recognition
and signalling functions [27]. TMOD2 is a tropomodulin specific
to neurons; tropomodulins cap the ends of actin filaments [28].
TAP1 is ‘transporter associated with antigen processing, involved
with transporting molecules across extra and intra cellular
membranes, associated with the MHC [29]. HLA-F is another
human leukocyte antigen (component of the MHC). ZAP-70 is
zeta-chain-associated protein kinase 70, another component of the
TCR [30]. EOMES is eomesodermin, which encodes a transcrip-
tion factor which is thought to be necessary for the differentiation
of effector CD8+ T cells [31]. AP1G1 is AP-1 complex subunit
gamma-1, which has a role in promoting the formation of clathrin-
Table 4. Null subnetwork analysis.
No. nodes No. null subnetworks
Expected false positive
subnets per dataset
Min no. subnets
per dataset Max FDR
3 40124 4.0 4 1
4 3392 0.34 1 0.34
5 365 0.037 1 0.037
6 48 0.0048 1 0.0048
7 4 461024 1 461024
8 1 161024 1 161024
104 iterations of null subnetworks were generated, by the same subnetwork identification method as used for the real data sets, but based on p-values randomly
sampled from a uniform distribution. The table shows the number of subnetworks of each size which were declared as significant by the subnetwork identification
method based on these null p-values, out of the 104 iterations. The table also shows the minimum number of subnetworks of each size detected in any of the real data
sets (see table 3), and corresponding conservative estimates of the FDR, defined as the number of false positives divided by the number of discoveries, for each size of
subnetwork.
doi:10.1371/journal.pone.0084573.t004
Table 5. Directionality of significant network edges.
Data set Prop. HR.1
BLCA 0.32
BRCA 0.46
HNSC 0.47
KIRC 0.82
LUAD 0.66
LUSC 0.66
UCEC 0.37
The numbers in the second column indicate the proportion of network edges
(i.e., pairs of genes) which increase (rather than decrease) their ‘network
interaction co-ordinatedness’ for worse disease prognosis (i.e., the DNAm
network correlation measure increases for shorter typical patient survival time,
HRw1).
doi:10.1371/journal.pone.0084573.t005
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Figure 3. Smaller significant network modules: network diagrams. Network edges displayed in green and red indicate positive and negative
hazard ratios, respectively, for the DNAm network correlation measure corresponding to that interaction; these correspond, respectively, to an
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coated pits and vesicles, which are used to transport molecules
within and between cells [32].
Larger Significant Subnetworks
In each of two data sets, KIRC and LUAD, a larger significant
subnetwork was also found (with 770 and 373 nodes respectively),
and these are shown in figure 4; the higher density of nodes in the
case of the KIRC large subnetwork is clearly seen in this figure.
Both these large subnetworks were found to be biologically
relevant, with 474 and 156 gene sets respectively found as
significant by GSEA (qv0:05). Degree distributions on a linear,
and on a log-log scale, are shown in figure 5; there is power-law
type behaviour in both cases for degree in the range 2 to 8 (linear
model lines estimating the logarithm of the degree distribution,
with corresponding slope estimates, are shown in the figure).
Considering the p-value histograms in figure 2, there are many
more significant p-values for KIRC and LUAD than the other
data sets, as can be seen by the height of the histogram bars closest
to p~0, and correspondingly more significant network edges for
these data sets. This may be why these data sets are the only ones
for which such large subnetworks are found. Most of the data sets
considered in this study have small sample sizes, particularly with
respect to the number of events, and hence relatively low statistical
power. If these methods were applied to larger data sets, larger
subnetworks such as these might be able to be found for other
cancer types. The degree density also decreases less as degree
increases in the case of KIRC (figure 5 (b), slope =21.8) than in
the case of LUAD (figure 5 (b), slope =22.6). This is as might be
expected given that there are more significant network edges in the
case of KIRC than LUAD (figure 2). This has the implication that
LUAD shows fewer nodes of very high numbers of connections, so
called ‘‘hubs’’ (see also tables S5 and S6). The presence of ‘‘hubs’’
is related to the probability of network failure. If a few nodes
control the connectivity of the whole network, then their
elimination will make the network fail. If the degree distribution
is more even, and thus the slope less steep, then the network may
be more resilient to failure. The slope is therefore an important
characteristic of the network.
One feature of interest in relation to these two larger significant
subnetworks is that they contain a high proportion of pairs of
genes (i.e., network edges) which increase their ‘network interac-
tion co-ordinatedness’, the worse the prognosis of the cancer. In
fact, this is a characteristic of the KIRC and LUAD data sets
particularly, although not of all the data sets (table 5). This could
be another reason why such large subnetworks are found for these
data sets. Whereas interactions which correspond to a decrease in
interactive behaviour with disease progression might logically
correspond to fragmented, smaller motifs and modules, interac-
tions which correspond to an increase in interactive behaviour
with disease progression might be expected to coalesce to form
larger subnetworks, with a tendency to act more autonomously.
Details about the genes/nodes in the top 5% of the degree
distribution (as a summary of the most significant nodes) and the
25 most significantly enriched gene sets are shown in table S5
(KIRC) and table S6 (LUAD). It is particularly noticeable that
there is enrichment by the genes in the significant large
subnetworks of many genes sets associated with transcriptional
and translational processes, and perhaps the most interesting of
these in the context of DNAm relate to splicing. For example, the
splicing factor gene SF3B4 is the node with the second highest
degree in the KIRC large subnetwork (table S5 (a)), and the
KEGG spliceosome gene set is very significantly enriched by the
nodes of the KIRC large subnetwork, OR~5:7 (95% C.I. 3.5–
9.2), FDR-adjusted p~8:7|10{9 (Fishers exact test), table S5 (b).
DNA methylation has been suggested to have an important
association with alternative splicing [33], although how this might
work is poorly understood. It is very interesting that the largest
significant subnetworks identified by this method appear to be
involved in these processes, amongst other forms of gene
regulatory behaviour, and more generally cancer-related process-
es.
Discussion
A DNA methylation (DNAm) measure of network correlation
has been developed, as a measure of ‘network interaction co-
ordinatedness’, between pairs of genes, in terms of their DNAm
profiles. This measure has been shown to be highly associated with
the correlation of gene expression measurements (at the mRNA
level) from the same pairs of genes in five independent data sets
increase and decrease in ‘network interaction co-ordinatedness’ for worse disease prognosis. (a) Wound healing module (KIRC). (b) Immune module
(UCEC). (c) Mitochondial module (LUAD). (d) MAP-kinase module (LUSC). (e) Largest biologically significant subnetwork in the BLCA data set. (f)
Largest biologically significant subnetwork in the BRCA data set. Further details about the corresponding network nodes (genes) and significantly
enriched gene sets appear in tables 6–9 and S1–4.
doi:10.1371/journal.pone.0084573.g003
Table 6. Wound-healing module: gene/node details.
Gene/node Degree Chr Gene info
ELANE 6 19 elastase, neutrophil expressed
ITGAM 2 16 integrin, alpha M (complement component 3 receptor 3 subunit)
CSF3 1 17 colony stimulating factor 3 (granulocyte)
F2R 1 5 coagulation factor II (thrombin) receptor
F5 1 1 coagulation factor V (proaccelerin, labile factor)
KNG1 1 3 kininogen 1
SERPINE1 1 7 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type
1), member 1
THY1 1 11 Thy-1 cell surface antigen
Gene/node details for the wound healing module found as significant in the KIRC data set.
doi:10.1371/journal.pone.0084573.t006
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from different cancer types; i.e., the DNAm network correlation
measure reflects well co-regulatory behaviour relating to gene
expression. This measure has been tested for association with
patient overall survival outcome independent of known clinical
prognostic features in nine independent data sets corresponding to
different cancer types; independent association with survival
outcome was found for this measure in seven out of nine of these
data sets, with strong association in five of these, which are Breast
Invasive Carcinoma (BRCA), Kidney Renal Clear Cell Carcino-
ma (KIRC), Lung Adenocarcinoma (LUAD), Lung Squamous
Cell Carcinoma (LUSC), and Uterine Corpus Endometrioid
Carcinoma (UCEC). For each of these data sets (cancer types),
Table 7. Wound-healing module: significantly enriched gene sets.
Gene set OR (95% C.I.) q-val
BLOOD_COAGULATION 290 (52–1600) 5.3e-05
COAGULATION 290 (52–1600) 5.3e-05
HEMOSTASIS 250 (46–1500) 5.7e-05
WOUND_HEALING 230 (42–1300) 5.9e-05
REGULATION_OF_BODY_FLUID_LEVELS 210 (37–1100) 7e-05
KEGG_COMPLEMENT_AND_COAGULATION_CASCADES 200 (36–1100) 7e-05
BIOCARTA_INTRINSIC_PATHWAY 450 (63–2600) 0.00023
NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS 320 (45–1800) 0.00054
WANG_ESOPHAGUS_CANCER_VS_NORMAL_UP 100 (19–580) 0.00057
PID_INTEGRIN2_PATHWAY 230 (34–1300) 0.001
REGULATION_OF_BIOLOGICAL_QUALITY 50 (9.7–320) 0.0014
RESPONSE_TO_WOUNDING 69 (13–380) 0.0019
PID_UPA_UPAR_PATHWAY 170 (25–940) 0.0019
REACTOME_HEMOSTASIS 41 (7.9–260) 0.003
REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION 54 (9.9–290) 0.0044
BIOCARTA_FIBRINOLYSIS_PATHWAY 680 (53–8200) 0.006
RESPONSE_TO_EXTERNAL_STIMULUS 42 (7.8–230) 0.0092
REACTOME_RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2_ 86 (13–450) 0.0092
BIOCARTA_GRANULOCYTES_PATHWAY 460 (38–4100) 0.0094
RECEPTOR_BINDING 35 (6.6–190) 0.016
BIOCARTA_EXTRINSIC_PATHWAY 310 (27–2200) 0.017
REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS 52 (7.9–270) 0.032
RPS14_DN.V1_UP 47 (7.2–250) 0.041
Significantly enriched gene sets, for the wound healing module found as significant in the KIRC data set. Q-values indicate significance of enrichment in the
corresponding gene set by the genes in this module, calculated according to a one-sided Fisher’s exact test. Further details about these gene sets can be found from
the website of the Broad Institute Molecular Signatures Database (http://www.broadinstitute.org).
doi:10.1371/journal.pone.0084573.t007
Table 8. Immune module: gene/node details.
Gene/node Degree Chr Gene info
HLA-A 8 6 major histocompatibility complex, class I, A
ITGAV 2 2 integrin, alpha V
TAP1 2 6 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
AP1G1 1 16 adaptor-related protein complex 1, gamma 1 subunit
CD247 1 1 CD247 molecule
EOMES 1 3 eomesodermin
SDCBP 1 8 syndecan binding protein (syntenin)
TMOD2 1 15 tropomodulin 2 (neuronal)
ZAP70 1 2 zeta-chain (TCR) associated protein kinase 70 kDa
HLA-F 1 6 major histocompatibility complex, class I, F
SDC4 1 20 syndecan 4
Gene/node details for the immune module found as significant in the UCEC data set.
doi:10.1371/journal.pone.0084573.t008
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significant subnetworks, modules, and motifs have been found,
with the associated false discovery rate shown to be well-controlled
for those with at least 5 nodes (genes). In many cases, these
significant subnetwork modules are shown to have strong
correlation with groups of genes previously found to be biologically
relevant, in the context of cancer biology.
The smaller significant subnetwork modules identified in
relation to previous knowledge of cancer biology include ones
identified with wound healing (associated with cancer invasion and
progression to new sites), mitochondrial function (associated with
increased energy production required for cancer proliferation),
immune function (associated with stifling the body’s ability to fight
the cancer), and MAP-kinase signalling (associated with regulation
of cell proliferation). The wound healing module interactions show
an increase in network co-ordinatedness with worsening disease
prognosis, indicating a tendency towards a re-wiring of this
module in support of metastatic processes. The immune module
interactions show a decrease in network co-ordinatedness with
worsening disease prognosis, suggesting a degradation of the
body’s own defences against the tumour. Larger significant
subnetworks found are associated, amongst other things, with
functions related to DNA transcription, translation and regulation.
These functions notably include those related to splicing, which is
of particular interest in relation to current DNAm research.
Wound healing is an example of a biological function which
behaves aberrantly in the context of cancer biology, highlighted in
a recent paper [34] which fundamentally shifts the paradigm of
oncogenesis. Those authors suggest that tumourigenic processes
are actually a regression to archaic metazoan phenotypic
characteristics normally suppressed in healthy tissue, which
Table 9. Immune module: significantly enriched gene sets.
Gene set OR (95% C.I.) q-val
REACTOME_ADAPTIVE_IMMUNE_SYSTEM 37 (9.3–170) 0.001
REACTOME_ANTIGEN_PROCESSING_CROSS_PRESENTATION 97 (20–390) 0.0019
REACTOME_ANTIGEN_PRESENTATION_FOLDING_ASSEMBLY_AND_PEPTIDE_LOADING_OF_CLASS_I_MHC 210 (33–980) 0.0036
REACTOME_THE_ROLE_OF_NEF_IN_HIV1_REPLICATION_AND_DISEASE_PATHOGENESIS 140 (23–670) 0.006
REACTOME_IMMUNE_SYSTEM 22 (5.5–100) 0.006
KEGG_CELL_ADHESION_MOLECULES_CAMS 52 (11–210) 0.0069
GNF2_HLA-C 110 (17–480) 0.0094
GNF2_INPP5D 100 (17–460) 0.0094
GNF2_ITGAL 100 (16–440) 0.0094
REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL 89 (15–390) 0.012
RECEPTOR_COMPLEX 76 (13–330) 0.013
GNF2_CD53 80 (13–350) 0.013
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION 76 (13–330) 0.013
PID_CD8TCRDOWNSTREAMPATHWAY 80 (13–350) 0.013
PID_CD8TCRPATHWAY 71 (12–310) 0.014
REACTOME_ER_PHAGOSOME_PATHWAY 71 (12–310) 0.014
REACTOME_ENDOSOMAL_VACUOLAR_PATHWAY 370 (32–2500) 0.015
DER_IFN_ALPHA_RESPONSE_UP 66 (11–290) 0.015
PID_IL12_2PATHWAY 65 (11–280) 0.015
BIOCARTA_TCRA_PATHWAY 310 (27–2200) 0.015
REACTOME_NEF_MEDIATED_DOWNREGULATION_OF_MHC_CLASS_I_COMPLEX_CELL_SURFACE_EXPRESSION 310 (27–2200) 0.015
REACTOME_TRANSLOCATION_OF_ZAP_70_TO_IMMUNOLOGICAL_SYNAPSE 310 (27–2200) 0.015
DER_IFN_GAMMA_RESPONSE_UP 61 (10–270) 0.015
BIOCARTA_CTL_PATHWAY 270 (24–1600) 0.018
MODULE_293 270 (24–1600) 0.018
REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION 27 (5.8–110) 0.018
IMMUNOLOGICAL_SYNAPSE 230 (21–1400) 0.021
MODULE_143 210 (19–1200) 0.025
GNF2_MATK 140 (14–820) 0.043
KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY 38 (6.4–160) 0.043
SENGUPTA_EBNA1_ANTICORRELATED 38 (6.4–160) 0.043
GNF2_ZAP70 130 (13–740) 0.045
BIOCARTA_CSK_PATHWAY 130 (13–740) 0.045
Significantly enriched gene sets, for the immune module found as significant in the UCEC data set. Q-values indicate significance of enrichment in the corresponding
gene set by the genes in this module, calculated according to a one-sided Fisher’s exact test. Further details about these gene sets can be found from the website of the
Broad Institute Molecular Signatures Database (http://www.broadinstitute.org).
doi:10.1371/journal.pone.0084573.t009
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correspond to groups of cells behaving more autonomously. The
key point in this metazoan model is that, whereas the conventional
model of tumourigenesis holds that proliferative characteristics
acquired by cancers occur as a result of random genetic and
epigenetic mutation, these archaic metazoan characteristics are
present in humans all along, but lie dormant until they are released
in cancer. The data considered in this study does not allow this
point to be addressed directly, but intuitively it seems that our
findings fit well into this new metazoan oncogenic paradigm.
The quality of the presented study depends on the availability of
clinical data. However, information is missing for many samples
for several clinical covariates. Also, for a number of clinical
covariates, the large majority of the samples are in the same
category for that covariate. It should therefore be expected that
this analysis will not have fully taken account of some clinical
covariates. Further, the clinical information considered does not
include descriptions of applied therapies. For these reasons, more
detailed analyses relating to specific cancers should be expected to
be necessary for the further development of clinical biomarkers
based on the methods developed here.
While the data sets considered in this study do not contain
enough events to train a predictive model, bigger data sets would
allow such predictive prognostic models to be defined using these
methods, leading to novel independent DNAm-based disease
prognostic biomarkers. Such biomarkers would be based on DNA
rather than RNA, and would be ideal for further investigation and
development using current state-the-art and future research
findings from the rapidly advancing field of network science.
Methods and Models
Data Download and Preprocessing
DNA methylation (DNAm) data, collected via the Illumina
Infinium HumanMethylation450 platform, were downloaded
from The Cancer Genome Atlas (TCGA) project [9–11] at level
3. These data were obtained for nine different tumour types, as
follows: Bladder Urothelial Carcinoma (BLCA), Breast Invasive
Carcinoma (BRCA), Colon Adenocarcinoma (COAD), Head and
Neck Squamous Cell Carcinoma (HNSC), Kidney Renal Clear
Cell Carcinoma (KIRC), Liver (LIHC), Lung Adenocarcinoma
(LUAD), Lung Squamous Cell Carcinoma (LUSC), and Uterine
Corpus Endometrioid Carcinoma (UCEC).
These data were pre-processed by first removing probes with
non-unique mappings and which map to SNPs (as identified in the
TCGA level 3 data); probes mapping to sex chromosomes were
also removed; in total 98384 probes were removed in this way
from all data sets. After removal of these probes, 270985 probes
with known gene annotations remained. Individually for each data
set, probes were then removed if they had less than 95% coverage
across samples; probe values were also replaced if they had
corresponding detection p-value greater than 5%, by KNN (k
nearest neighbour) imputation (k~5). The loci of analysed CpGs
were mapped to genes based on annotation information for the
Illumina Infinium platform obtained from the R [35]/Bioconduc-
tor [36] package ‘IlluminaHumanMethylation450 k’. The data
were also checked for batch effects by hierarchical clustering and
correlation of the significant principle components with phenotype
and batch: no significant batch effects (which would warrant
further correction) were found.
A list of pairs of genes, each pair corresponding to a known
biochemical interaction in humans, was downloaded from http://
www.pathwaycommons.org, and was used as a canonical human
interactome map in the subsequent analysis. In this network
model, each pair of genes defines a network edge (422481 edges in
total), with individual genes represented by network nodes (12726
nodes in total).
For each data set/cancer type, clinical information was also
downloaded, for the variables overall survival status (alive or not),
overall survival time (i.e., time to last follow up or time to death), as
well as several clinical covariates for each data set, such as age,
disease stage (I–IV), disease grade (1–3), and residual disease status
(present or not). All survival analyses were carried out using the R
[35] package ‘survival’.
For five of the cancer types (BRCA, COAD, KIRK, LUSC and
UCEC), gene expression data were also downloaded from TCGA
at level 3. These data were quantile-normalised.
Figure 4. Larger significant subnetworks: network diagrams. Network edges displayed in green and red indicate positive and negative
hazard ratios, respectively, for the DNAm network correlation measure corresponding to that interaction; these correspond, respectively, to an
increase and decrease in ‘network interaction co-ordinatedness’ for worse disease prognosis. (a) the KIRC large subnetwork. (b) the LUAD large
subnetwork. Further details about the corresponding network nodes (genes) for the top 5% of the degree distribution and top 25 significantly
enriched gene sets appear in tables S5–6.
doi:10.1371/journal.pone.0084573.g004
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DNA Methylation Network Correlation Measure
Definitions
Canonical correlation analysis (CCA) [8] seeks to find the
vectors a and b, in the p and q dimensional spaces of variables
X~(x1,x2,:::,xp)’ and Y~(y1,y2,:::,yq)’ respectively, which max-
imise the correlation r~cor a’X,b’Yð Þ, defined according to
equation 1,
r~
a’SXYbﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
a’SXXa
p ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
b’SYYb
p ð1Þ
where SXX~E (X{mX)(X{mX)’½  and
SYY~E (Y{mY)(Y{mY)’½  are the covariance matrices of X and
Y respectively, and SXY~E (X{mX)(Y{mY)’½  is the cross-
covariance matrix of X and Y.
Two genes X and Y , which are joined by a network edge in the
interactome map (i.e., these genes or their products participate in
some canonical biochemical interaction), have corresponding
methylation profiles which are measured for sample/patient j at
p and q CpGs (loci) respectively along these genes. Denoting these
measurements by the variables x1,:::xp and y1,:::,yq for genes X
and Y respectively, the DNA methylation profiles for these genes,
for patient j, can be represented by the vectors x(j) and y(j), which
have p and q entries respectively. A measure of DNAm network
correlation rxy(j), of the methylation profiles of genes X and Y for
sample j, can then be defined by analogy with equation 1,
according to equation 2,
r^xy(j)~
x(j)T S^(h)XYy(j)ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
x(j)T S^(h)XXx(j)
q ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
y(j)T S^(h)YYy(j)
q ð2Þ
where S^(h)XX , S^
(h)
YY and S^
(h)
XY are estimated from healthy rather than
cancer samples in the methylation data set, according to equations
3–5,
S^
(h)
XX~
1
nh
X
j[healthy
x(j){m^
(h)
X
 
x(j){m^
(h)
X
 T
ð3Þ
Figure 5. Larger significant subnetworks: degree distributions. Degree distributions (kernel-smoothed) on linear and log scales, for (a), (b)
KIRC large subnetwork, and (c), (d) LUAD large subnetwork. Dashed red lines on the log-log plots display the power-law linear model line of best fit,
estimated from the nodes with degree in the range 2 to 8, with the corresponding slope value (i.e., power law exponential coefficient) displayed
above.
doi:10.1371/journal.pone.0084573.g005
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S^
(h)
YY~
1
nh
X
j[healthy
y(j){m^
(h)
Y
 
y(j){m^
(h)
Y
 T
(4)
S^(h)XY~
1
nh
X
j[healthy
x(j){m^(h)X
 
y(j){m^(h)Y
 T
ð5Þ
where
m^
(h)
X ~
1
nh
X
j [ healthy
x(j)
and
m^
(h)
Y ~
1
nh
X
j [ healthy
y(j)
and nh is the number of healthy samples in the data set.
Selection of Significant Clinical Covariates
If a clinical covariate (e.g., age, disease stage and grade, or
presence of residual disease) associates significantly with the
patient outcome of interest (here, overall survival time) and also
with the predictors of interest (here, the DNAm network
correlation measure), then any association between the predictors
and outcome of interest might be due only to the variation of the
clinical covariate(s). In order to develop novel DNA methylation
biomarkers which are independent of known prognostic clinical
features, the statistical tests of association with patient survival
outcome are adjusted here for the clinical covariates which also
associate significantly with patient survival outcome.
For each data set (corresponding to a particular cancer type),
the available clinical covariates were tested one by one for
association with overall survival outcome, by fitting a Cox model.
For each data set, the covariates for which this association
corresponded to pv0:1 were then considered further, in a
multivariate Cox model. Because clinical covariates may be
measuring correlated physiological quantities (e.g., height and
weight, or in some cases disease stage and grade), it is only
necessary to adjust for a clinical covariate in the subsequent
DNAm survival analysis if that clinical covariate associates
significantly with survival after adjustment for the other clinical
covariates. Therefore, the clinical covariates found to be significant
in the first stage (by testing their association one by one with with
overall survival outcome) were tested against each other in a
multivariate Cox regression, and those which remained significant
(pv0:1) after adjustment for the other clinical covariates were
then adjusted for in the subsequent DNAm survival analysis.
For each data set, the clinical covariates which were considered
are as follows, with those ultimately found to associate with overall
survival (pv0:1), and thus adjusted for in the DNAm survival
analysis, shown in bold.
N BLCA: stage, age, grade, diagnosis subtype, anatomic organ
subdivision, height, prior diagnosis, gender, tobacco history,
weight.
N BRCA: age, residual disease, stage, gender, ER status, PR
status.
N COAD: age, stage, prior diagnosis, residual disease, anatomic
site, histology, polyps, lymphatic invasion, perineural invasion,
gender, height, weight.
N HNSC: residual disease, tobacco history, age, stage,
grade, prior diagnosis, pack years, lymph node presentation,
gender.
N KIRC: age, stage, prior diagnosis, residual disease,
grade, haemoglobin, platelet, lymph node, calcium, gender.
N LIHC: creatinine, prothrombin, age, stage, grade, prior
diagnosis, residual disease, prospective tissue collection,
platelet, albumin, alpha fetoprotein, fibrosis, gender, height,
weight.
N LUAD: residual disease, age, stage, tobacco history, prior
diagnosis, gender.
N LUSC: residual disease, age, stage, tobacco history,
gender.
N UCEC: stage, residual disease, age, grade, prior diagno-
sis, height, weight.
Supporting Information
Figure S1 p-value heatmaps, showing the association of
the DNAm network correlation measure with patient
overall survival outcome, for the BRCA data set. For the
BRCA data set, for each network edge (DNAm network
interaction correlation measure), the Cox regression p-value
(adjusted for clinical covariates) of association with patient survival
outcome is displayed according to the colour scale shown on the
right. (a) p-values are calculated for every possible pair of genes of
the 14800 available in this data set, with genes clustered along the
margins of the plot using these p-values as a distance measure. (b)
Null p-values are generated by sampling from a uniform
distribution bounded on [0,1] for every possible pair of
genes, with genes similarly clustered along the margins. (c) and
(e) p-values are calculated for the 8614 genes which appear in
this data set and also in the pathway commons interactome
map, for the 276136 interactions between pairs of these genes
defined by this interactome map. Genes are similarly clustered
along the margins of the plot according to p-value. (e) Shows a
zoomed-in view of the top-left of (c). (d) and (f) are as (c) and (e),
but based on null p-values randomly sampled from a uniform (0,1)
distribution, to demonstrate the structure present from the
pathway commons interactome map, without the influence of
the DNA methylation network interaction measure. Pearson
correlation coefficients comparing values in these adjacency
matrices as plotted, are as follows: (a) vs. (b), 0.0011; (c) vs. (d),
0.26; (e) vs. (f), 0.38.
(JPG)
Table S1 Mitochondrial module.
(PDF)
Table S2 MAP-kinase module.
(PDF)
Table S3 Largest biologically significant module,
BLCA.
(PDF)
Table S4 Largest biologically significant module,
BRCA.
(PDF)
Table S5 KIRC large subnetwork.
(PDF)
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Table S6 LUAD large subnetwork.
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